Addex Therapeutics

CEO Tim Dyer has long experience with Addex and meaningful shareholdings, and the team has navigated complex transactions. Still, the score reflects mixed operating results: a key partnered asset was terminated by Janssen, the company remains pre‑revenue, and financing remains precarious. Governance and disclosure quality in filings is adequate.

To earn a higher score, we would need to see durable funding, disciplined dilution control, and tangible clinical progress translating into predictable value creation.